Advertisement
HLN vs TAK
Which Stock Would AI Choose? Haleon (HLN) vs. Takeda Pharmaceutical (TAK) Stock Comparison
Key Takeaways
- HLN, a consumer healthcare leader, has faced pressure from a weak cold and flu season in recent weeks, contributing to year-to-date declines of around 8-9%.
- TAK, a biopharmaceutical giant, shows positive year-to-date gains of about 5%, supported by clinical trial successes like TAK-881 meeting endpoints.
- Both stocks have declined roughly 7-9% over the past month amid broader market volatility, but TAK boasts stronger one-year performance at 14-16% versus HLN's 12-14% drop.
- HLN trades at a more attractive P/E ratio (around 18) compared to TAK's elevated 70+, highlighting valuation contrasts.
- Pipeline catalysts favor TAK with recent positive trial data, while HLN benefits from steady oral health demand.
- Sector exposure differs: HLN in stable consumer health, TAK in higher-risk pharma with growth potential.
Introduction
This stock comparison between HLN and TAK examines two healthcare firms navigating distinct challenges in the current market. HLN represents consumer-driven stability, while TAK embodies biopharma innovation. Traders seeking relative performance insights and investors eyeing sector trade-offs will find value here, particularly amid recent volatility from seasonal demand shifts and clinical developments. The analysis highlights price behavior, sentiment, and positioning for informed decision-making in healthcare allocations.
HLN Overview and Recent Performance
Haleon plc (HLN) is a leading consumer healthcare company, spun off from GSK in 2022, specializing in over-the-counter products like Sensodyne toothpaste, Centrum vitamins, and pain relief under brands such as Panadol. Headquartered in the UK, it operates globally with a focus on oral health, vitamins, minerals, supplements (VMS), and digestive health.
In recent market activity, HLN shares have traded around $9.11, down approximately 2% in recent sessions and 7-8% over the past month. Year-to-date, the stock is off 8-9%, underperforming broader indices amid a weak cold and flu season that pressured respiratory sales. However, strong toothpaste demand and US rebound expectations helped maintain full-year guidance despite slightly below-estimate organic growth. Sentiment reflects resilience in core categories, with analysts noting robust oral health performance offsetting seasonal headwinds.
TAK Overview and Recent Performance
Takeda Pharmaceutical Company Limited (TAK) is Japan's largest pharma firm, focusing on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. With a diversified global footprint—over 50% US revenue—it develops treatments like Entyvio for inflammatory diseases.
Recent weeks saw TAK shares near $16.46, down 1% daily and 8-10% monthly, reflecting broader pullbacks. Yet, year-to-date gains stand at 5%, with one-year returns of 14-16%, outperforming HLN. Positive topline results from the Phase 2/3 TAK-881 trial in primary immunodeficiency disease boosted sentiment, alongside advancements in Crohn's and pediatric studies. Strategic shifts, like ending some collaborations, underscore pipeline prioritization amid cost-cutting.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that collectively trade thousands of different tickers across stocks, ETFs, and crypto. Out of 351 total AI bots, over 25 trending ones are highlighted for their suitability in current market conditions, focusing on high-growth sectors like semiconductors, industrials, AI infrastructure, volatility plays, and gold miners. These bots employ diverse strategies—momentum, sector rotation, swing trading—with impressive stats: annualized returns up to +285%, win rates of 50-88%, and profit factors reaching 11.7. Many handle multi-ticker portfolios (up to 18 symbols), offering signal, virtual, and brokerage agents with risk management. Explore these for potential outperformance tailored to today's dynamics.
Head-to-Head Comparison
HLN and TAK diverge in business models: HLN's consumer health emphasizes recurring OTC sales for stability, while TAK's biopharma relies on prescription drugs and R&D pipelines for higher growth but elevated risks from trials and patents.
Growth drivers contrast too—HLN leverages everyday essentials like oral care amid demographic trends, versus TAK's catalysts in rare diseases and oncology. Recent momentum favors TAK YTD, though both lag monthly; risk factors include seasonal volatility for HLN and partnership shifts for TAK. Sector exposure positions HLN defensively, TAK offensively. Market sentiment tilts toward TAK's upgrades, but HLN's lower P/E offers value trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently leans toward TAK based on superior trend consistency year-to-date, pipeline catalysts like TAK-881 success, and relative positioning with analyst upgrades amid restructuring. While HLN provides stability and valuation appeal, TAK's growth prospects in biopharma suggest higher probabilistic upside in the near term, barring unforeseen trial risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLN is a StrongBuy and TAK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HLN’s FA Score shows that 1 FA rating(s) are green whileTAK’s FA Score has 1 green FA rating(s).
- HLN’s FA Score: 1 green, 4 red.
- TAK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HLN’s TA Score shows that 6 TA indicator(s) are bullish while TAK’s TA Score has 6 bullish TA indicator(s).
- HLN’s TA Score: 6 bullish, 3 bearish.
- TAK’s TA Score: 6 bullish, 2 bearish.
Price Growth
HLN (@Pharmaceuticals: Generic) experienced а +3.12% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +1.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.11%. For the same industry, the average monthly price growth was +1.35%, and the average quarterly price growth was +10.85%.
Reported Earning Dates
HLN is expected to report earnings on Jul 30, 2026.
TAK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+1.11% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| HLN | TAK | HLN / TAK | |
| Capitalization | 40.4B | 49.7B | 81% |
| EBITDA | 2.86B | 1.24T | 0% |
| Gain YTD | -7.396 | 2.053 | -360% |
| P/E Ratio | 17.92 | 41.88 | 43% |
| Revenue | 11B | 4.47T | 0% |
| Total Cash | N/A | 762B | - |
| Total Debt | N/A | 4.85T | - |
TAK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | |
SMR RATING 1..100 | 90 | |
PRICE GROWTH RATING 1..100 | 59 | |
P/E GROWTH RATING 1..100 | 84 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| HLN | TAK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 2 days ago 38% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 42% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 29% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 36% |
| TrendWeek ODDS (%) | 2 days ago 52% | 2 days ago 42% |
| TrendMonth ODDS (%) | 2 days ago 51% | 2 days ago 42% |
| Advances ODDS (%) | 3 days ago 54% | 16 days ago 44% |
| Declines ODDS (%) | 17 days ago 53% | 3 days ago 46% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 41% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 55% |
Advertisement
HLN and
Correlation & Price change
A.I.dvisor indicates that over the last year, HLN has been loosely correlated with TAK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if HLN jumps, then TAK could also see price increases.
| Ticker / NAME | Correlation To HLN | 1D Price Change % | ||
|---|---|---|---|---|
| HLN | 100% | -0.32% | ||
| TAK - HLN | 39% Loosely correlated | +1.66% | ||
| ZTS - HLN | 32% Poorly correlated | -2.22% | ||
| COLL - HLN | 30% Poorly correlated | +5.02% | ||
| LFCR - HLN | 27% Poorly correlated | -4.36% | ||
| RDY - HLN | 26% Poorly correlated | +0.85% | ||
More | ||||
TAK and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | +1.66% | ||
| HLN - TAK | 38% Loosely correlated | -0.32% | ||
| AMRX - TAK | 34% Loosely correlated | -0.46% | ||
| ANIK - TAK | 29% Poorly correlated | +3.28% | ||
| VTRS - TAK | 26% Poorly correlated | +1.62% | ||
| COLL - TAK | 26% Poorly correlated | +5.02% | ||
More | ||||